<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on May 13, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">Registration No. 333- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">REGISTRATION STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">THE SECURITIES ACT OF 1933</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>Oncobiologics,
Inc.</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of Registrant as specified in its
charter)</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Delaware</B></FONT></P></td>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></td>
    <TD STYLE="width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 9pt"><B>38-3982704</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 9pt">(State or other jurisdiction of Incorporation or organization)</font></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 9pt">(I.R.S. Employer Identification No.)</font></td></tr>
</table>
<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>7 Clarke Drive</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Cranbury, New Jersey 08512</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address of principal executive offices) (Zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2011 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2015 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2016 Employee Stock Purchase Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Full title of the plan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pankaj Mohan, Ph.D.</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Chairman, President and Chief Executive Officer</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Oncobiologics, Inc.</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>7 Clarke Drive</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Cranbury, New Jersey 08512</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(609) 619-3990</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Name and address of agent for service) (Telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 50%; text-align: center">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Yvan-Claude Pierre</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Daniel I. Goldberg</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Marianne C. Sarrazin</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Cooley LLP</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>1114 Avenue of the Americas</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>New York, New York 10036</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>(212) 479-6000</b></P></td>
    <TD STYLE="width: 50%; text-align: center">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Lawrence A. Kenyon</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Chief Financial Officer</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Oncobiologics, Inc.</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>7 Clarke Drive</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Cranbury, New Jersey 08512</b></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>(609) 619-3990</b></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 92%; border-collapse: collapse; margin-left: 0.3in">
<tr style="vertical-align: top">
    <TD STYLE="width: 69%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Large accelerated filer&nbsp;&nbsp;<font style="font-family: Wingdings">&#168;</font></font></td>
    <TD STYLE="width: 31%; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Accelerated filer &nbsp;&nbsp;<font style="font-family: Wingdings">&#168;</font></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Non-accelerated filer&nbsp;&nbsp;<font style="font-family: Wingdings">x</font> (Do not check if a smaller reporting company)</font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Smaller reporting company&nbsp;&nbsp;<font style="font-family: Wingdings">&#168;</font></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 36%; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Title of Securities </b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>to be Registered</b></P></td>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 13%; border-top: Black 1.5pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center"><b>Amount to be</b><br>
<b>Registered(1)</b></td>
    <TD NOWRAP STYLE="vertical-align: top; width: 6%; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 14%; border-top: Black 1.5pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proposed</b><br>
        <b>Maximum</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Offering</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price per Share</b></P></td>
    <TD NOWRAP STYLE="vertical-align: top; width: 4%; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 14%; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proposed</b><br>
        <b>Maximum</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Offering Price</b></P></td>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 13%; border-top: Black 1.5pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Amount of</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Registration</b><br>
        <b>Fee</b></P></td></tr>
<tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 7.5pt; text-indent: -7.5pt">Common Stock, par value $0.01 per share, reserved for issuance pursuant to the 2015 Equity Incentive Plan</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">149,917 (2)(3)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 3pt; text-align: center">$6.00(8)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">&nbsp;$899,502.00</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$90.58</td></tr>
<tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 7.5pt; text-indent: -7.5pt">Common Stock, par value $0.01 per share, reserved for issuance pursuant<font style="background-color: white"> to restricted stock unit awards outstanding under</font> the 2015 Equity Incentive Plan</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">1,096,460 (4)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 3pt; text-align: center">$6.00 (9)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">$6,578,760.00</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">$662.48</td></tr>
<tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 7.5pt; text-indent: -7.5pt">Common Stock, par value $0.01 per share, reserved for issuance pursuant to the 2016 Employee Stock Purchase Plan</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">289,855 (5)(6)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 3pt; text-align: center">$6.00 (10)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">$1,739,130.00</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">$175.13</td></tr>
<tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 7.5pt; text-indent: -7.5pt">Common Stock, par value $0.01 per share, reserved for issuance pursuant<font style="background-color: white"> to performance stock unit awards outstanding under</font> the 2011 Stock Incentive Plan</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: left">&nbsp;&nbsp;249,510 (7)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 3pt; text-align: center">&nbsp;$6.35 (11)</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: right">$1,584,388.50</td>
    <td style="border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center">$159.55</td></tr>
<tr>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 6pt">Total</td>
    <td style="border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt; text-align: right">1,785,742</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt; text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt; text-align: right">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt; text-align: right">$10,801,780.5</td>
    <td style="border-bottom: Black 1.5pt double; padding-right: 6pt; padding-left: 6pt; text-align: center">$1,087.74(12)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
this Registration Statement shall also cover any additional shares of Registrant&rsquo;s common stock, par value $0.01 (the &ldquo;<B>Common
Stock</B>&rdquo;), that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization
or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant&rsquo;s common
stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Represents 149,917 shares of the Registrant&rsquo;s Common Stock reserved for future issuance under the Oncobiologics, Inc.
2015 Equity Incentive Plan (the &ldquo;<B>2015 EIP</B>&rdquo;) as of the date of this Registration Statement. Pursuant to the terms
of the 2015 EIP, any shares subject to outstanding awards granted under the 2015 EIP that expire or terminate, or are forfeited,
for any reason prior to exercise or settlement, shall become available for issuance under the 2015 EIP, subject to certain limitations.
See footnote 4 below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">The number of shares of Common Stock reserved for issuance under the 2015 EIP will automatically increase on (i) the date that
is sixty (60) calendar days following the date of the underwriting agreement between the Registrant and the underwriters managing
the initial public offering of the Common Stock (the &ldquo;<B>IPO Date</B>&rdquo;) by an amount of shares of Common Stock equal
to 3% of the total number of shares of Common Stock outstanding on such sixtieth (60<SUP>th</SUP>) day following the IPO Date,
and (ii) January 1<SUP>st</SUP> of each year, starting on January 1, 2017 and continuing through January 1, 2026, in an amount
equal to the lesser of (A) 3% of the total number of shares of Common Stock outstanding on December 31<SUP>st </SUP>of the immediately
preceding calendar year and (B)&nbsp;a number determined by the Registrant&rsquo;s board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Represents 1,096,460 shares of Registrant&rsquo;s Common Stock reserved for issuance upon the settlement of outstanding restricted
stock unit awards granted under the 2015 EIP as of the date of this Registration Statement. <FONT STYLE="background-color: white">To
the extent that any outstanding awards under the 2015 EIP expire or are forfeited subsequent to the date of this Registration Statement,
the shares of the Registrant&rsquo;s </FONT>Common Stock<FONT STYLE="background-color: white"> reserved for issuance pursuant to
such awards will become available for issuance under the 2015 EIP</FONT> subject to certain limitations<FONT STYLE="background-color: white">.
See footnote 2 above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Represents 289,855 shares of Registrant&rsquo;s Common Stock reserved for future issuance under the Oncobiologics, Inc. 2016
Employee Stock Purchase Plan (the &ldquo;<B>2016 ESPP</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">The number of shares reserved for issuance under the 2016 ESPP will automatically increase on January 1st each year, starting
on January 1, 2017 and continuing through January 1, 2026, by the lesser of (i) one percent (1%) of the total number of shares
of the Registrant&rsquo;s Common Stock outstanding on December 31st of the preceding calendar year, (ii) 1,760,000 shares of Common
Stock and (iii) a number determined by the Registrant&rsquo;s board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Represents 249,510 shares of Registrant&rsquo;s Common Stock reserved for issuance upon the settlement of outstanding performance
stock unit awards (&ldquo;<B>PSUs</B>&rdquo;) granted under the Oncobiologics, Inc. 2011 Stock Incentive Plan (the &ldquo;<B>2011
Plan</B>&rdquo;) as of the date of this Registration Statement. The 2011 Plan has been terminated and no further awards will be
granted pursuant to the 2011 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of <FONT STYLE="background-color: white">the
initial public offering price of $</FONT>6<FONT STYLE="background-color: white">.00 per share of Common Stock included in the Units
as set forth in the Registrant&rsquo;s Registration Statement on Form S-1 (File No.&nbsp;333-209011) declared effective on May&nbsp;</FONT>12<FONT STYLE="background-color: white">,
2016. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of <FONT STYLE="background-color: white">the
initial public offering price of $</FONT>6<FONT STYLE="background-color: white">.00 per share of Common Stock included in the Units
as set forth in the Registrant&rsquo;s Registration Statement on Form S-1 (File No.&nbsp;333-209011) declared effective on May&nbsp;</FONT>12<FONT STYLE="background-color: white">,
2016. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration
fee on the basis of 85% of the initial public offering price of $</FONT>6<FONT STYLE="background-color: white">.00 per share of
Common Stock included in the Units as set forth in the Registrant&rsquo;s Registration Statement on Form S-1 (File No. 333-209011)
declared effective on May </FONT>12<FONT STYLE="background-color: white">, 2016. Pursuant to the 2016 ESPP, the purchase price
of the shares of the Registrant&rsquo;s</FONT> Common Stock<FONT STYLE="background-color: white"> reserved for issuance thereunder
will be at least 85% of the lower of the fair market value of the Registrant&rsquo;s </FONT>Common Stock<FONT STYLE="background-color: white">
on the first trading day of the offering period or on the exercise date. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD STYLE="text-align: justify">Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $6.35,
the weighted-average exercise price for outstanding PSUs granted pursuant to the 2011 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD STYLE="text-align: justify">Filing fee &thinsp;previously paid with <FONT STYLE="background-color: white">the Registrant&rsquo;s Registration Statement
on Form S-1 (File No. 333-209011) on January 15, 2016</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 3.</B></TD><TD STYLE="text-align: justify"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The following documents filed by Oncobiologics,
Inc. (the &ldquo;<B>Registrant</B>&rdquo;) with the Securities and Exchange Commission are incorporated by reference into this
Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>The
Registrant&rsquo;s prospectus filed on May 13, 2016 pursuant to Rule 424(b) under the Securities Act, relating to the Registration
Statement on Form S-1 (File No. 333-209011), which contains audited financial statements for the Registrant&rsquo;s latest fiscal
year for which such statements have been filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>The
description of the Registrant&rsquo;s Common Stock which is contained in the Registrant&rsquo;s Registration Statement on Amendment
No. 1 to Form 8-A filed on May 11, 2016 (File No. 001-37759) under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), including any amendment or report filed for the purpose of updating such description.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>All
documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections&nbsp;13(a), 13(c),
14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K and exhibits
furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of
a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters
all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part
hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that
a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies
or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 4.</B></TD><TD STYLE="text-align: justify"><B>DESCRIPTION OF SECURITIES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">See the description of the Registrant&rsquo;s
Common Stock contained in the Registrant&rsquo;s Registration Statement on Form S-1 (File No. 333-209011).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 5.</B></TD><TD STYLE="text-align: justify"><B>INTERESTS OF NAMED EXPERTS AND COUNSEL</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 6.</B></TD><TD STYLE="text-align: justify"><B>INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The Registrant is incorporated under the laws
of the State of Delaware. Section 102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate
the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of
fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware
corporate law or obtained an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Section 145 of the DGCL provides that a corporation
has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request
of the corporation in related capacities against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid
in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or
is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to
be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that,
despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">As permitted by the DGCL, the Registrant&rsquo;s
amended and restated certificate of incorporation and amended and restated bylaws provide that: (i) the Registrant is required
to indemnify its directors to the fullest extent permitted by the DGCL; (ii) the Registrant may, in its discretion, indemnify its
officers, employees and agents as set forth in the DGCL; (iii) the Registrant is required, upon satisfaction of certain conditions,
to advance all expenses incurred by its directors in connection with certain legal proceedings; (iv) the rights conferred in the
bylaws are not exclusive; and (v) the Registrant is authorized to enter into indemnification agreements with its directors, officers,
employees and agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The Registrant has entered into agreements with
its directors and executive officers that require the Registrant to indemnify them against all expenses, judgments, penalties,
fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, in connection with
any proceeding or any claim, issue or matter therein, if the person acted in good faith and in a manner the person reasonably believed
to be in or not opposed to the best interests of the Registrant, and with respect to any criminal proceeding, had no reasonable
cause to believe the person&rsquo;s conduct was unlawful. The indemnification agreements also set forth certain procedures that
will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves
any of the Registrant&rsquo;s directors or officers regarding which indemnification is sought, nor is the Registrant aware of any
threatened litigation that may result in claims for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt; background-color: white">The
Registrant maintains a directors&rsquo; and officers&rsquo; liability insurance policy. The policy insures directors and officers
against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the
Registrant for those losses for which it has lawfully indemnified the directors and officers. The policy contains various exclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 7.</B></TD><TD STYLE="text-align: justify"><B>EXEMPTION FROM REGISTRATION CLAIMED.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 8.</B></TD><TD STYLE="text-align: justify"><B>EXHIBITS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.75pt solid"><b>Number</b></P></td>
    <TD>&nbsp;</td>
    <td colspan="2" style="text-decoration: underline"><b><u>Description</u></b>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp; 4.1</td>
    <TD>(1)</td>
    <TD COLSPAN="2" STYLE="text-align: justify">Certificate of Incorporation of Oncobiologics, Inc., as presently in effect.</td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">4.2</P></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2)</P></td>
    <td colspan="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certificate of Amendment of Certificate of Incorporation, dated
        April 26, 2016.</P></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp; 4.3</td>
    <TD>(3)</td>
    <TD COLSPAN="2" STYLE="text-align: justify">Form of Amended and Restated Certificate of Incorporation of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp; 4.4</td>
    <TD>(4)</td>
    <TD COLSPAN="2" STYLE="text-align: justify">Bylaws of Oncobiologics, Inc., as presently in effect.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp; 4.5</td>
    <TD>(5)</td>
    <TD COLSPAN="2" STYLE="text-align: justify">Form of Amended and Restated Bylaws of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp; 5.1</td>
    <td colspan="2">&nbsp;</td>
    <TD>Opinion of Cooley LLP.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;23.1</td>
    <td colspan="2">&nbsp;</td>
    <TD STYLE="text-align: justify">Consent of Independent Registered Public Accounting Firm.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;23.2</td>
    <td colspan="2">&nbsp;</td>
    <TD>Consent of Cooley LLP (included in Exhibit&nbsp;5.1).</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;24.1</td>
    <td colspan="2">&nbsp;</td>
    <TD>Power of Attorney (see signature page hereto).</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;99.1</td>
    <TD>(6)</td>
    <td colspan="2">2011 Stock Incentive Plan.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2">&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">99.2</td>
    <td colspan="2" >(7)</td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Form of Amended and Restated Performance Stock Unit Agreement
for 2011 Stock Incentive Plan.</P></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">99.3</td>
    <td colspan="2">(8)</td>
    <TD>2015 Equity Incentive Plan.</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 8%; text-align: right">&nbsp;99.4</td>
    <TD STYLE="width: 4%">(9)</td>
    <TD STYLE="width: 88%; text-align: justify">Forms of agreements and award grant notices 2015 Equity Incentive Plan.</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;99.5</td>
    <TD>(10)</td>
    <TD STYLE="text-align: justify">2016 Employee Stock Purchase Plan.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.1 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.2 to Registrant&rsquo;s Amendment No. 3 to the registration statement on Form S-1 (File No. 333-209011),
filed with the Commission on April 27, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.4 to the Registrant&rsquo;s Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.3 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.5 to the Registrant&rsquo;s Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.2 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.29 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on April 27, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.3 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.4 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrant&rsquo;s registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.</B></TD><TD STYLE="text-align: justify"><B>UNDERTAKINGS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.</B></FONT></TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To include any prospectus
required by Section 10(a)(3) of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><I>provided, however</I>, that paragraphs (a)(i)
and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to section&nbsp;13 or section&nbsp;15(d) of the
Exchange Act that are incorporated by reference in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The portion of any
other free writing prospectus relating to the offering containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.</B></FONT></TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange
Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to section 15(d) of the Exchange
Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating
to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form&nbsp;S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Cranbury, New Jersey, on May 13, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <td colspan="2"><font style="font-variant: small-caps"><b>Oncobiologics, Inc.</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</td>
    <TD STYLE="width: 3%">&nbsp;</td>
    <TD STYLE="width: 47%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>By:</td>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Pankaj Mohan</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>Pankaj Mohan, Ph.D.</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><i>Chairman, President and Chief Executive Officer</i></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">KNOW ALL BY THESE PRESENTS,
that each person whose signature appears below hereby constitutes and appoints Pankaj Mohan, Ph.D. and Lawrence A. Kenyon, and
each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or each of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 40%; border-bottom: Black 1pt solid; text-align: center"><b>Signature</b></td>
    <td style="width: 2%; text-align: center">&nbsp;</td>
    <td style="width: 35%; border-bottom: Black 1pt solid; text-align: center"><b>Title</b></td>
    <td style="width: 2%; text-align: center">&nbsp;</td>
    <td style="width: 21%; border-bottom: Black 1pt solid; text-align: center"><b>Date</b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Pankaj Mohan, Ph.D.</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Chairman, President and Chief Executive </td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Pankaj Mohan, Ph.D.</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Officer</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">(Principal Executive Officer)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Lawrence A. Kenyon</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Chief Financial Officer</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Lawrence A. Kenyon</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;(Principal Accounting and Financial Officer)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Todd C. Brady, M.D., Ph.D.</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Todd C. Brady, M.D., Ph.D.</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Scott Canute</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Scott Canute</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Albert D. Dyrness</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Albert D. Dyrness</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Donald J. Griffith</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Donald J. Griffith</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Kurt J. Hilzinger</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Kurt J. Hilzinger</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid">/s/ Robin Smith Hoke</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td>&nbsp;</td>
    <td>May 13, 2016</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Robin Smith Hoke</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.75pt solid"><B>Number</B></P></TD>
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 89%; font: 10pt Times New Roman, Times, Serif; text-decoration: underline"><B><U>Description</U></B>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.1(1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certificate of Incorporation of Oncobiologics, Inc., as presently in effect.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.2(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certificate of Amendment of Certificate of Incorporation, dated April 26, 2016.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.3(3)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Form of Amended and Restated Certificate of Incorporation of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.4(4)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Bylaws of Oncobiologics, Inc., as presently in effect.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">4.5(5)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Form of Amended and Restated Bylaws of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">5.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Opinion of Cooley LLP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">23.1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">23.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consent of Cooley LLP (included in Exhibit&nbsp;5.1).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">24.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Power of Attorney (see signature page hereto).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">99.1(6)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">2011 Stock Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">99.2(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Form of Amended and Restated Performance Stock Unit Agreement for 2011 Stock Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">99.3(8)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">99.4(9)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Forms of agreements and award grant notices 2015 Equity Incentive Plan.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">99.5(10)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">2016 Employee Stock Purchase Plan.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.1 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.2 to Registrant&rsquo;s Amendment No. 3 to the registration statement on Form S-1 (File No. 333-209011),
filed with the Commission on April 27, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.4 to the Registrant&rsquo;s Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.3 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 3.5 to the Registrant&rsquo;s Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.2 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.29 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on April 27, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.3 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.4 to the Registrant&rsquo;s registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD STYLE="text-align: justify">Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrant&rsquo;s registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "t1601338_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 95342}]
{"company-data": {"conformed-name": "Oncobiologics, Inc.", "cik": "0001649989", "assigned-sic": "2836", "irs-number": "383982704", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-211362", "film-number": "161648754"}, "business-address": {"street1": "7 CLARKE DRIVE", "city": "CRANBURY", "state": "NJ", "zip": "08512", "phone": "6096193990"}, "mail-address": {"street1": "7 CLARKE DRIVE", "city": "CRANBURY", "state": "NJ", "zip": "08512"}}
As filed with the Securities and Exchange
Commission on May 13, 2016
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Oncobiologics,
Inc.
(Exact name of Registrant as specified in its
charter)
Delaware
38-3982704
(State or other jurisdiction of Incorporation or organization)
(I.R.S. Employer Identification No.)
7 Clarke Drive
Cranbury, New Jersey 08512
(Address of principal executive offices) (Zip
code)
2011 Stock Incentive Plan
2015 Equity Incentive Plan
2016 Employee Stock Purchase Plan
(Full title of the plan)
Pankaj Mohan, Ph.D.
Chairman, President and Chief Executive Officer
Oncobiologics, Inc.
7 Clarke Drive
Cranbury, New Jersey 08512
(609) 619-3990
(Name and address of agent for service) (Telephone
number, including area code, of agent for service)
Copies to:
Yvan-Claude Pierre
Daniel I. Goldberg
Marianne C. Sarrazin
Cooley LLP
1114 Avenue of the Americas
New York, New York 10036
(212) 479-6000
Lawrence A. Kenyon
Chief Financial Officer
Oncobiologics, Inc.
7 Clarke Drive
Cranbury, New Jersey 08512
(609) 619-3990
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2
of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
x
(Do not check if a smaller reporting company)
Smaller reporting company
¨
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount to be
Registered(1)
Proposed
Maximum
Offering
Price per Share
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration
Fee
Common Stock, par value $0.01 per share, reserved for issuance pursuant to the 2015 Equity Incentive Plan
149,917 (2)(3)
$6.00(8)
$899,502.00
$90.58
Common Stock, par value $0.01 per share, reserved for issuance pursuant
to restricted stock unit awards outstanding under
the 2015 Equity Incentive Plan
1,096,460 (4)
$6.00 (9)
$6,578,760.00
$662.48
Common Stock, par value $0.01 per share, reserved for issuance pursuant to the 2016 Employee Stock Purchase Plan
289,855 (5)(6)
$6.00 (10)
$1,739,130.00
$175.13
Common Stock, par value $0.01 per share, reserved for issuance pursuant
to performance stock unit awards outstanding under
the 2011 Stock Incentive Plan
249,510 (7)
$6.35 (11)
$1,584,388.50
$159.55
Total
1,785,742
$10,801,780.5
$1,087.74(12)
(1)
Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "
Securities Act
"),
this Registration Statement shall also cover any additional shares of Registrant's common stock, par value $0.01 (the "
Common
Stock
"), that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization
or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's common
stock.
(2)
Represents 149,917 shares of the Registrant's Common Stock reserved for future issuance under the Oncobiologics, Inc.
2015 Equity Incentive Plan (the "
2015 EIP
") as of the date of this Registration Statement. Pursuant to the terms
of the 2015 EIP, any shares subject to outstanding awards granted under the 2015 EIP that expire or terminate, or are forfeited,
for any reason prior to exercise or settlement, shall become available for issuance under the 2015 EIP, subject to certain limitations.
See footnote 4 below.
(3)
The number of shares of Common Stock reserved for issuance under the 2015 EIP will automatically increase on (i) the date that
is sixty (60) calendar days following the date of the underwriting agreement between the Registrant and the underwriters managing
the initial public offering of the Common Stock (the "
IPO Date
") by an amount of shares of Common Stock equal
to 3% of the total number of shares of Common Stock outstanding on such sixtieth (60
th
) day following the IPO Date,
and (ii) January 1
st
of each year, starting on January 1, 2017 and continuing through January 1, 2026, in an amount
equal to the lesser of (A) 3% of the total number of shares of Common Stock outstanding on December 31
st
of the immediately
preceding calendar year and (B) a number determined by the Registrant's board of directors.
(4)
Represents 1,096,460 shares of Registrant's Common Stock reserved for issuance upon the settlement of outstanding restricted
stock unit awards granted under the 2015 EIP as of the date of this Registration Statement.
To
the extent that any outstanding awards under the 2015 EIP expire or are forfeited subsequent to the date of this Registration Statement,
the shares of the Registrant's
Common Stock
reserved for issuance pursuant to
such awards will become available for issuance under the 2015 EIP
subject to certain limitations
.
See footnote 2 above.
(5)
Represents 289,855 shares of Registrant's Common Stock reserved for future issuance under the Oncobiologics, Inc. 2016
Employee Stock Purchase Plan (the "
2016 ESPP
").
(6)
The number of shares reserved for issuance under the 2016 ESPP will automatically increase on January 1st each year, starting
on January 1, 2017 and continuing through January 1, 2026, by the lesser of (i) one percent (1%) of the total number of shares
of the Registrant's Common Stock outstanding on December 31st of the preceding calendar year, (ii) 1,760,000 shares of Common
Stock and (iii) a number determined by the Registrant's board of directors.
(7)
Represents 249,510 shares of Registrant's Common Stock reserved for issuance upon the settlement of outstanding performance
stock unit awards ("
PSUs
") granted under the Oncobiologics, Inc. 2011 Stock Incentive Plan (the "
2011
Plan
") as of the date of this Registration Statement. The 2011 Plan has been terminated and no further awards will be
granted pursuant to the 2011 Plan.
(8)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of
the
initial public offering price of $
6
.00 per share of Common Stock included in the Units
as set forth in the Registrant's Registration Statement on Form S-1 (File No. 333-209011) declared effective on May
12
,
2016.
(9)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of
the
initial public offering price of $
6
.00 per share of Common Stock included in the Units
as set forth in the Registrant's Registration Statement on Form S-1 (File No. 333-209011) declared effective on May
12
,
2016.
(10)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration
fee on the basis of 85% of the initial public offering price of $
6
.00 per share of
Common Stock included in the Units as set forth in the Registrant's Registration Statement on Form S-1 (File No. 333-209011)
declared effective on May
12
, 2016. Pursuant to the 2016 ESPP, the purchase price
of the shares of the Registrant's
Common Stock
reserved for issuance thereunder
will be at least 85% of the lower of the fair market value of the Registrant's
Common Stock
on the first trading day of the offering period or on the exercise date.
(11)
Estimated in accordance with Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $6.35,
the weighted-average exercise price for outstanding PSUs granted pursuant to the 2011 Plan.
(12)
Filing fee  previously paid with
the Registrant's Registration Statement
on Form S-1 (File No. 333-209011) on January 15, 2016
.
PART II
ITEM 3.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by Oncobiologics,
Inc. (the "
Registrant
") with the Securities and Exchange Commission are incorporated by reference into this
Registration Statement:
(a)
The
Registrant's prospectus filed on May 13, 2016 pursuant to Rule 424(b) under the Securities Act, relating to the Registration
Statement on Form S-1 (File No. 333-209011), which contains audited financial statements for the Registrant's latest fiscal
year for which such statements have been filed.
(b)
The
description of the Registrant's Common Stock which is contained in the Registrant's Registration Statement on Amendment
No. 1 to Form 8-A filed on May 11, 2016 (File No. 001-37759) under the Securities Exchange Act of 1934, as amended (the "
Exchange
Act
"), including any amendment or report filed for the purpose of updating such description.
(c)
All
documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c),
14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits
furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of
a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters
all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part
hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that
a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies
or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Registration Statement.
ITEM 4.
DESCRIPTION OF SECURITIES
See the description of the Registrant's
Common Stock contained in the Registrant's Registration Statement on Form S-1 (File No. 333-209011).
ITEM 5.
INTERESTS OF NAMED EXPERTS AND COUNSEL
Not applicable.
ITEM 6.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Registrant is incorporated under the laws
of the State of Delaware. Section 102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate
the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of
fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware
corporate law or obtained an improper personal benefit.
Section 145 of the DGCL provides that a corporation
has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request
of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid
in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or
is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to
be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that,
despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
As permitted by the DGCL, the Registrant's
amended and restated certificate of incorporation and amended and restated bylaws provide that: (i) the Registrant is required
to indemnify its directors to the fullest extent permitted by the DGCL; (ii) the Registrant may, in its discretion, indemnify its
officers, employees and agents as set forth in the DGCL; (iii) the Registrant is required, upon satisfaction of certain conditions,
to advance all expenses incurred by its directors in connection with certain legal proceedings; (iv) the rights conferred in the
bylaws are not exclusive; and (v) the Registrant is authorized to enter into indemnification agreements with its directors, officers,
employees and agents.
The Registrant has entered into agreements with
its directors and executive officers that require the Registrant to indemnify them against all expenses, judgments, penalties,
fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, in connection with
any proceeding or any claim, issue or matter therein, if the person acted in good faith and in a manner the person reasonably believed
to be in or not opposed to the best interests of the Registrant, and with respect to any criminal proceeding, had no reasonable
cause to believe the person's conduct was unlawful. The indemnification agreements also set forth certain procedures that
will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves
any of the Registrant's directors or officers regarding which indemnification is sought, nor is the Registrant aware of any
threatened litigation that may result in claims for indemnification.
The
Registrant maintains a directors' and officers' liability insurance policy. The policy insures directors and officers
against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the
Registrant for those losses for which it has lawfully indemnified the directors and officers. The policy contains various exclusions.
ITEM 7.
EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
ITEM 8.
EXHIBITS
Exhibit
Number
Description
4.1
(1)
Certificate of Incorporation of Oncobiologics, Inc., as presently in effect.
4.2
(2)
Certificate of Amendment of Certificate of Incorporation, dated
        April 26, 2016.
4.3
(3)
Form of Amended and Restated Certificate of Incorporation of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.
4.4
(4)
Bylaws of Oncobiologics, Inc., as presently in effect.
4.5
(5)
Form of Amended and Restated Bylaws of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.
5.1
Opinion of Cooley LLP.
23.1
Consent of Independent Registered Public Accounting Firm.
23.2
Consent of Cooley LLP (included in Exhibit 5.1).
24.1
Power of Attorney (see signature page hereto).
99.1
(6)
2011 Stock Incentive Plan.
99.2
(7)
Form of Amended and Restated Performance Stock Unit Agreement
for 2011 Stock Incentive Plan.
99.3
(8)
2015 Equity Incentive Plan.
99.4
(9)
Forms of agreements and award grant notices 2015 Equity Incentive Plan.
99.5
(10)
2016 Employee Stock Purchase Plan.
(1)
Previously filed as Exhibit 3.1 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.
(2)
Previously filed as Exhibit 3.2 to Registrant's Amendment No. 3 to the registration statement on Form S-1 (File No. 333-209011),
filed with the Commission on April 27, 2016, and incorporated by reference herein.
(3)
Previously filed as Exhibit 3.4 to the Registrant's Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.
(4)
Previously filed as Exhibit 3.3 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.
(5)
Previously filed as Exhibit 3.5 to the Registrant's Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.
(6)
Previously filed as Exhibit 10.2 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(7)
Previously filed as Exhibit 10.29 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on April 27, 2016, and incorporated by reference herein.
(8)
Previously filed as Exhibit 10.3 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(9)
Previously filed as Exhibit 10.4 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(10)
Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrant's registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.
ITEM 9.
UNDERTAKINGS
1.
The undersigned registrant hereby undertakes:
(a)
To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)           To include any prospectus
required by Section 10(a)(3) of the Securities Act;
(ii)          To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective registration statement.
(iii)          To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;
provided, however
, that paragraphs (a)(i)
and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the
Exchange Act that are incorporated by reference in the registration statement.
(b)
That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(c)
To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(d)
That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)            Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii)           Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;
(iii)          The portion of any
other free writing prospectus relating to the offering containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant; and
(iv)          Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.
2.
The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange
Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange
Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating
to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Cranbury, New Jersey, on May 13, 2016.
Oncobiologics, Inc.
By:
/s/ Pankaj Mohan
Pankaj Mohan, Ph.D.
Chairman, President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS,
that each person whose signature appears below hereby constitutes and appoints Pankaj Mohan, Ph.D. and Lawrence A. Kenyon, and
each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him
or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or each of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Pankaj Mohan, Ph.D.
Chairman, President and Chief Executive
May 13, 2016
Pankaj Mohan, Ph.D.
Officer
(Principal Executive Officer)
/s/ Lawrence A. Kenyon
Chief Financial Officer
May 13, 2016
Lawrence A. Kenyon
(Principal Accounting and Financial Officer)
/s/ Todd C. Brady, M.D., Ph.D.
Director
May 13, 2016
Todd C. Brady, M.D., Ph.D.
/s/ Scott Canute
Director
May 13, 2016
Scott Canute
/s/ Albert D. Dyrness
Director
May 13, 2016
Albert D. Dyrness
/s/ Donald J. Griffith
Director
May 13, 2016
Donald J. Griffith
/s/ Kurt J. Hilzinger
Director
May 13, 2016
Kurt J. Hilzinger
/s/ Robin Smith Hoke
Director
May 13, 2016
Robin Smith Hoke
EXHIBIT INDEX
Exhibit
Number
Description
4.1(1)
Certificate of Incorporation of Oncobiologics, Inc., as presently in effect.
4.2(2)
Certificate of Amendment of Certificate of Incorporation, dated April 26, 2016.
4.3(3)
Form of Amended and Restated Certificate of Incorporation of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.
4.4(4)
Bylaws of Oncobiologics, Inc., as presently in effect.
4.5(5)
Form of Amended and Restated Bylaws of Oncobiologics, Inc., to be in effect upon closing of its initial public offering.
5.1
Opinion of Cooley LLP.
23.1
Consent of Independent Registered Public Accounting Firm.
23.2
Consent of Cooley LLP (included in Exhibit 5.1).
24.1
Power of Attorney (see signature page hereto).
99.1(6)
2011 Stock Incentive Plan.
99.2(7)
Form of Amended and Restated Performance Stock Unit Agreement for 2011 Stock Incentive Plan.
99.3(8)
2015 Equity Incentive Plan.
99.4(9)
Forms of agreements and award grant notices 2015 Equity Incentive Plan.
99.5(10)
2016 Employee Stock Purchase Plan.
(1)
Previously filed as Exhibit 3.1 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.
(2)
Previously filed as Exhibit 3.2 to Registrant's Amendment No. 3 to the registration statement on Form S-1 (File No. 333-209011),
filed with the Commission on April 27, 2016, and incorporated by reference herein.
(3)
Previously filed as Exhibit 3.4 to the Registrant's Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.
(4)
Previously filed as Exhibit 3.3 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed with
the Commission on January 15, 2016, and incorporated by reference herein.
(5)
Previously filed as Exhibit 3.5 to the Registrant's Amendment No. 1 to the registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.
(6)
Previously filed as Exhibit 10.2 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(7)
Previously filed as Exhibit 10.29 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on April 27, 2016, and incorporated by reference herein.
(8)
Previously filed as Exhibit 10.3 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(9)
Previously filed as Exhibit 10.4 to the Registrant's registration statement on Form S-1 (File No. 333-209011), filed
with the Commission on January 15, 2016, and incorporated by reference herein.
(10)
Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrant's registration statement on Form S-1 (File No.
333-209011), filed with the Commission on February 12, 2016, and incorporated by reference herein.